

Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference

June 14, 2016 4:05 PM ET

FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 1:00 p.m. EDT at the St. Regis New York.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A replay of the webcast will be archived on Vitae's website for 90 days following the presentation.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae's lead clinical assets include VTP-43742, an oral ROR γ t inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXR β selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company's website at www.vitaepharma.com.

INVESTORS:

Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

MEDIA:

6 Degrees PR
Tony Plohoros
(908) 591-2839
tplohoros@6degreespr.com



Vitae Pharmaceuticals, Inc.